Abstract: The paper intends to interpret 2019 Guideline of Prevention and Treatment for Chronic Hepatitis B. In order to better understand the guideline(2019 edition) and guide clinical practice, we highlighted the differences between the version of 2019 and 2015 pertinent to the changes in clinical diagnostic indicators, modified antiviral treatment strategies, and the treatment recommendations for special patients. The indications for antiviral therapy are further expanded, in which recommendation of potent agent with low resistance as first-line drugs is emphasized, and the guidance to medication of special population is specified.

Key words: Chronic Hepatitis B, Antiviral agents, Guideline, Interpretation